Further National Microbiology Framework contract

RNS Number : 9199V
Yourgene Health PLC
19 April 2021
 

 

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

 

Further National Microbiology Framework contract award

 

Successful tender under Lot 4 ( Clinical Laboratory Diagnostic Testing Services ) valued at £15bn

 

Manchester, UK - 19 April 2021:   Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England ("PHE") has confirmed that Yourgene has been successful with its tender under PHE's National Microbiology Framework for Lot 4 (Clinical Laboratory Diagnostic Testing Services).

 

Lot 4 is a £15bn Framework to be satisfied over a period of four years by multiple successful bidders, with only 50 companies appointed to this lot.

 

PHE's National Microbiology Framework is appointing suppliers to framework agreements for four lots. Awards under Lot 1 and Lot 4 have been announced and cover the supply of Diagnostics Goods and Services, including Clinical Laboratory Diagnostic Testing Services. Yourgene announced earlier today that it had been successful with its tender for Lot 1 (Diagnostic Goods and Services) .

 

Yourgene will be able to offer its Clarigene ®   SARS-CoV-2 PCR assay and associated Manchester-based clinical laboratory testing services under the Framework Agreement .

 

Whilst the Framework Agreement is not exclusive to Yourgene, or a guarantee of orders, it does allow participating public health authorities across the UK to issue call-off contracts to procure goods and testing services from Yourgene, amongst other providers, going forward.

 

Lyn Rees, CEO of Yourgene commented:

"We are delighted with the further successful tender award under Lot 4 of the Microbiology Framework. This reinforces the reputation of our accredited lab based COVID testing services and we look forward to updating shareholders should we secure future call-off contracts under this framework agreement."

 

This announcement contains inside information for the purposes of UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgene-health.com

Barry Hextall, Chief Financial Officer

 

Joanne Cross, Director of Marketing

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: +44 (0)20 7213 0880

Liam Murray / James Caithie / Ludovico Lazzaretti

 

 

N+1 Singer (Joint Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas

 

 

 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Tel: +44 (0)20 7710 7600

Nicholas Moore / Matthew Blawat / Ben Maddison

 

 

 

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or  yourgene@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / Mob: 07584 391 303 

 

 

 

 

 

 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTMZGMDZLLGMZM
UK 100

Latest directors dealings